SLC5A2 and chronic kidney disease: When the data for patients with nondiabetic CKD from the DAPA-CKD and EMPA-KIDNEY trials were combined, compared with the placebo, SGLT-2 inhibitors reduced the risk of CKD progression by 30% (RR: 0.70; 95% CI: 0.50–1.00) in patients with ischemic or hypertensive nephropathy, by 40% (RR: 0.60; 95% CI: 0.46–0.78) in patients with glomerular diseases, and by 26% (RR: 0.74; 95% CI: 0.51–1.08) in patients with another or an unknown etiology of CKD [15].